{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:48:55Z","timestamp":1792057735704,"version":"4.4.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-77638-2","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:54:22Z","timestamp":1789404862000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preclinical and clinical investigation of VES001, an oral small molecule sortilin receptor inhibitor for the treatment of frontotemporal dementia: a first-in-human randomized placebo-controlled phase 1 trial"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2467-2253","authenticated-orcid":false,"given":"Louise","family":"Klem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2916-1130","authenticated-orcid":false,"given":"Daniel","family":"Dumas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imogen J.","family":"Swift","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie L.","family":"Frandsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ditte Nedergaard","family":"Mikkelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laerke","family":"Fensbaek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yal\u00e7in","family":"Yavuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Okke","family":"Merton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesminne","family":"Castricum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Prichardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2562-0364","authenticated-orcid":false,"given":"Graham M.","family":"Wynne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3725-5846","authenticated-orcid":false,"given":"Anders","family":"Riisager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul B.","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ove","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3907-072X","authenticated-orcid":false,"given":"Eva","family":"Thijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6422-6736","authenticated-orcid":false,"given":"Anders","family":"Nykjaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0483-841X","authenticated-orcid":false,"given":"Philip","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1043-6137","authenticated-orcid":false,"given":"Mads","family":"Kjolby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"77638_CR1","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/alz.12033","volume":"16","author":"T Miyagawa","year":"2020","unstructured":"Miyagawa, T. et al. Utility of the global CDR\u00ae plus NACC FTLD rating and development of scoring rules: data from the ARTFL\/LEFFTDS Consortium. Alzheimers Dement. 16, 106\u2013117 (2020).","journal-title":"Alzheimers Dement."},{"key":"77638_CR2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/j.1471-4159.2007.04968.x","volume":"104","author":"JL Eriksen","year":"2008","unstructured":"Eriksen, J. L. & Mackenzie, I. R. Progranulin: normal function and role in neurodegeneration. J. Neurochem. 104, 287\u2013297 (2008).","journal-title":"J. Neurochem."},{"key":"77638_CR3","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s12031-011-9538-y","volume":"45","author":"DS Knopman","year":"2011","unstructured":"Knopman, D. S. & Roberts, R. O. Estimating the number of persons with frontotemporal lobar degeneration in the US population. J. Mol. Neurosci. 45, 330\u2013335 (2011).","journal-title":"J. Mol. Neurosci."},{"key":"77638_CR4","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3109\/09540261.2013.776523","volume":"25","author":"CU Onyike","year":"2013","unstructured":"Onyike, C. U. & Diehl-Schmid, J. The epidemiology of frontotemporal dementia. Int. Rev. Psychiatry 25, 130\u2013137 (2013).","journal-title":"Int. Rev. Psychiatry"},{"key":"77638_CR5","doi-asserted-by":"publisher","first-page":"S96","DOI":"10.1017\/cjn.2016.25","volume":"43","author":"DB Hogan","year":"2016","unstructured":"Hogan, D. B. et al. The prevalence and incidence of frontotemporal dementia: a systematic review. Can. J. Neurol. Sci. 43, S96\u2013S109 (2016).","journal-title":"Can. J. Neurol. Sci."},{"key":"77638_CR6","doi-asserted-by":"publisher","first-page":"e2296","DOI":"10.1212\/WNL.0000000000011848","volume":"96","author":"JC Rojas","year":"2021","unstructured":"Rojas, J. C. et al. Plasma neurofilament light for prediction of disease progression in familial frontotemporal lobar degeneration. Neurology 96, e2296\u2013e2312 (2021).","journal-title":"Neurology"},{"key":"77638_CR7","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1001\/jamaneurol.2025.3307","volume":"82","author":"D Urso","year":"2025","unstructured":"Urso, D., Giannoni-Luza, S., Brayne, C., Ray, N. & Logroscino, G. Incidence and prevalence of frontotemporal dementia: a systematic review and meta-analysis. JAMA Neurol. 82, 1144\u20131152 (2025).","journal-title":"JAMA Neurol."},{"key":"77638_CR8","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.conb.2021.10.001","volume":"72","author":"S Amin","year":"2022","unstructured":"Amin, S., Carling, G. & Gan, L. New insights and therapeutic opportunities for progranulin-deficient frontotemporal dementia. Curr. Opin. Neurobiol. 72, 131\u2013139 (2022).","journal-title":"Curr. Opin. Neurobiol."},{"key":"77638_CR9","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/nature05016","volume":"442","author":"M Baker","year":"2006","unstructured":"Baker, M. et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442, 916\u2013919 (2006).","journal-title":"Nature"},{"key":"77638_CR10","doi-asserted-by":"publisher","first-page":"781","DOI":"10.3233\/JAD-2011-111046","volume":"27","author":"M Carecchio","year":"2011","unstructured":"Carecchio, M. et al. Cerebrospinal fluid biomarkers in Progranulin mutations carriers. J. Alzheimers Dis. 27, 781\u2013790 (2011).","journal-title":"J. Alzheimers Dis."},{"key":"77638_CR11","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.tig.2008.01.004","volume":"24","author":"M Cruts","year":"2008","unstructured":"Cruts, M. & Van Broeckhoven, C. Loss of progranulin function in frontotemporal lobar degeneration. Trends Genet. 24, 186\u2013194 (2008).","journal-title":"Trends Genet."},{"key":"77638_CR12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3233\/JAD-2010-1225","volume":"19","author":"D Galimberti","year":"2010","unstructured":"Galimberti, D. et al. GRN variability contributes to sporadic frontotemporal lobar degeneration. J. Alzheimers Dis. 19, 171\u2013177 (2010).","journal-title":"J. Alzheimers Dis."},{"key":"77638_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13024-018-0288-y","volume":"13","author":"S Beel","year":"2018","unstructured":"Beel, S. et al. Progranulin reduces insoluble TDP-43 levels, slows down axonal degeneration and prolongs survival in mutant TDP-43 mice. Mol. Neurodegener. 13, 55 (2018).","journal-title":"Mol. Neurodegener."},{"key":"77638_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-10-105","volume":"10","author":"Y Egashira","year":"2013","unstructured":"Egashira, Y. et al. The growth factor progranulin attenuates neuronal injury induced by cerebral ischemia-reperfusion through the suppression of neutrophil recruitment. J. Neuroinflammation 10, 105 (2013).","journal-title":"J. Neuroinflammation"},{"key":"77638_CR15","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3389\/fncel.2020.00260","volume":"14","author":"Z Guan","year":"2020","unstructured":"Guan, Z., Chen, Z., Fu, S., Dai, L. & Shen, Y. Progranulin administration attenuates beta-amyloid deposition in the hippocampus of 5xFAD mice through modulating BACE1 expression and microglial phagocytosis. Front. Cell Neurosci. 14, 260 (2020).","journal-title":"Front. Cell Neurosci."},{"key":"77638_CR16","doi-asserted-by":"publisher","first-page":"e13368","DOI":"10.1371\/journal.pone.0013368","volume":"5","author":"AS Laird","year":"2010","unstructured":"Laird, A. S. et al. Progranulin is neurotrophic in vivo and protects against a mutant TDP-43 induced axonopathy. PLoS ONE 5, e13368 (2010).","journal-title":"PLoS ONE"},{"key":"77638_CR17","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.1172\/JCI63113","volume":"122","author":"LH Martens","year":"2012","unstructured":"Martens, L. H. et al. Progranulin deficiency promotes neuroinflammation and neuron loss following toxin-induced injury. J. Clin. Investig. 122, 3955\u20133959 (2012).","journal-title":"J. Clin. Investig."},{"key":"77638_CR18","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ajpath.2010.11.002","volume":"178","author":"F Pickford","year":"2011","unstructured":"Pickford, F. et al. Progranulin is a chemoattractant for microglia and stimulates their endocytic activity. Am. J. Pathol. 178, 284\u2013295 (2011).","journal-title":"Am. J. Pathol."},{"key":"77638_CR19","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1126\/science.1199214","volume":"332","author":"W Tang","year":"2011","unstructured":"Tang, W. et al. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science 332, 478\u2013484 (2011).","journal-title":"Science"},{"key":"77638_CR20","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.brainres.2011.11.063","volume":"1436","author":"J Tao","year":"2012","unstructured":"Tao, J., Ji, F., Wang, F., Liu, B. & Zhu, Y. Neuroprotective effects of progranulin in ischemic mice. Brain Res 1436, 130\u2013136 (2012).","journal-title":"Brain Res"},{"key":"77638_CR21","doi-asserted-by":"publisher","first-page":"e97032","DOI":"10.1371\/journal.pone.0097032","volume":"9","author":"JM Van Kampen","year":"2014","unstructured":"Van Kampen, J. M., Baranowski, D. & Kay, D. G. Progranulin gene delivery protects dopaminergic neurons in a mouse model of Parkinson\u2019s disease. PLoS ONE 9, e97032 (2014).","journal-title":"PLoS ONE"},{"key":"77638_CR22","doi-asserted-by":"publisher","first-page":"e0182896","DOI":"10.1371\/journal.pone.0182896","volume":"12","author":"JM Van Kampen","year":"2017","unstructured":"Van Kampen, J. M. & Kay, D. G. Progranulin gene delivery reduces plaque burden and synaptic atrophy in a mouse model of Alzheimer\u2019s disease. PLoS ONE 12, e0182896 (2017).","journal-title":"PLoS ONE"},{"key":"77638_CR23","doi-asserted-by":"publisher","first-page":"2326.e5","DOI":"10.1016\/j.neurobiolaging.2011.06.017","volume":"32","author":"J Xu","year":"2011","unstructured":"Xu, J. et al. Extracellular progranulin protects cortical neurons from toxic insults by activating survival signaling. Neurobiol. Aging 32, 2326.e5\u201316 (2011).","journal-title":"Neurobiol. Aging"},{"key":"77638_CR24","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1084\/jem.20091568","volume":"207","author":"F Yin","year":"2010","unstructured":"Yin, F. et al. Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. J. Exp. Med. 207, 117\u2013128 (2010).","journal-title":"J. Exp. Med."},{"key":"77638_CR25","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1083\/jcb.201502029","volume":"210","author":"X Zhou","year":"2015","unstructured":"Zhou, X. et al. Prosaposin facilitates sortilin-independent lysosomal trafficking of progranulin. J. Cell Biol. 210, 991\u20131002 (2015).","journal-title":"J. Cell Biol."},{"key":"77638_CR26","doi-asserted-by":"crossref","unstructured":"Holler, C. J., Taylor, G., Deng, Q. & Kukar, T. Intracellular proteolysis of progranulin generates stable, lysosomal granulins that are haploinsufficient in patients with frontotemporal dementia caused by GRN mutations. eNeuro 4, ENEURO.0100-17.2017 (2017).","DOI":"10.1523\/ENEURO.0100-17.2017"},{"key":"77638_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-017-0196-6","volume":"12","author":"CW Lee","year":"2017","unstructured":"Lee, C. W. et al. The lysosomal protein cathepsin L is a progranulin protease. Mol. Neurodegener. 12, 55 (2017).","journal-title":"Mol. Neurodegener."},{"key":"77638_CR28","first-page":"969","volume":"26","author":"Y Tanaka","year":"2017","unstructured":"Tanaka, Y. et al. Progranulin regulates lysosomal function and biogenesis through acidification of lysosomes. Hum. Mol. Genet. 26, 969\u2013988 (2017).","journal-title":"Hum. Mol. Genet."},{"key":"77638_CR29","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1093\/hmg\/ddz229","volume":"29","author":"C Valdez","year":"2020","unstructured":"Valdez, C., Ysselstein, D., Young, T. J., Zheng, J. & Krainc, D. Progranulin mutations result in impaired processing of prosaposin and reduced glucocerebrosidase activity. Hum. Mol. Genet. 29, 716\u2013726 (2020).","journal-title":"Hum. Mol. Genet."},{"key":"77638_CR30","doi-asserted-by":"publisher","first-page":"4651","DOI":"10.1016\/j.cell.2021.08.002","volume":"184","author":"T Logan","year":"2021","unstructured":"Logan, T. et al. Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic. Cell 184, 4651\u20134668.e25 (2021).","journal-title":"Cell"},{"key":"77638_CR31","doi-asserted-by":"publisher","unstructured":"Robinson, S. et al. Enhanced legumain activity links progranulin deficiency to TDP-43 pathology in frontotemporal lobar degeneration. bioRxiv https:\/\/doi.org\/10.1101\/2024.01.16.575687 (2024).","DOI":"10.1101\/2024.01.16.575687"},{"key":"77638_CR32","doi-asserted-by":"publisher","first-page":"109692","DOI":"10.18632\/oncotarget.22766","volume":"8","author":"H Ding","year":"2017","unstructured":"Ding, H. et al. Progranulin derived engineered protein Atsttrin suppresses TNF-alpha-mediated inflammation in intervertebral disc degenerative disease. Oncotarget 8, 109692\u2013109702 (2017).","journal-title":"Oncotarget"},{"key":"77638_CR33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1750-1326-7-33","volume":"7","author":"J Gass","year":"2012","unstructured":"Gass, J. et al. Progranulin regulates neuronal outgrowth independent of sortilin. Mol. Neurodegener. 7, 33 (2012).","journal-title":"Mol. Neurodegener."},{"key":"77638_CR34","doi-asserted-by":"publisher","first-page":"E2849","DOI":"10.1073\/pnas.1722344115","volume":"115","author":"AD Nguyen","year":"2018","unstructured":"Nguyen, A. D. et al. Murine knockin model for progranulin-deficient frontotemporal dementia with nonsense-mediated mRNA decay. Proc. Natl. Acad. Sci. USA 115, E2849\u2013E2858 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"77638_CR35","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1007\/s13238-015-0213-x","volume":"6","author":"BC Wang","year":"2015","unstructured":"Wang, B. C., Liu, H., Talwar, A. & Jian, J. New discovery rarely runs smooth: an update on progranulin\/TNFR interactions. Protein Cell 6, 792\u2013803 (2015).","journal-title":"Protein Cell"},{"key":"77638_CR36","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1167\/iovs.64.7.8","volume":"64","author":"TS Jakobsen","year":"2023","unstructured":"Jakobsen, T. S. et al. Sortilin inhibition protects neurons from degeneration in the diabetic retina. Invest. Ophthalmol. Vis. Sci. 64, 8 (2023).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"77638_CR37","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nature02319","volume":"427","author":"A Nykjaer","year":"2004","unstructured":"Nykjaer, A. et al. Sortilin is essential for proNGF-induced neuronal cell death. Nature 427, 843\u2013848 (2004).","journal-title":"Nature"},{"key":"77638_CR38","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.tins.2012.01.003","volume":"35","author":"A Nykjaer","year":"2012","unstructured":"Nykjaer, A. & Willnow, T. E. Sortilin: a receptor to regulate neuronal viability and function. Trends Neurosci. 35, 261\u2013270 (2012).","journal-title":"Trends Neurosci."},{"key":"77638_CR39","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13024-022-00576-2","volume":"17","author":"A Salasova","year":"2022","unstructured":"Salasova, A., Monti, G., Andersen, O. M. & Nykjaer, A. Finding memo: versatile interactions of the VPS10p-Domain receptors in Alzheimer\u2019s disease. Mol. Neurodegener. 17, 74 (2022).","journal-title":"Mol. Neurodegener."},{"key":"77638_CR40","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/nn2000","volume":"10","author":"P Jansen","year":"2007","unstructured":"Jansen, P. et al. Roles for the pro-neurotrophin receptor sortilin in neuronal development, aging and brain injury. Nat. Neurosci. 10, 1449\u20131457 (2007).","journal-title":"Nat. Neurosci."},{"key":"77638_CR41","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nn.2689","volume":"14","author":"CB Vaegter","year":"2011","unstructured":"Vaegter, C. B. et al. Sortilin associates with Trk receptors to enhance anterograde transport and neurotrophin signaling. Nat. Neurosci. 14, 54\u201361 (2011).","journal-title":"Nat. Neurosci."},{"key":"77638_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04251-y","volume":"21","author":"M Kurnellas","year":"2023","unstructured":"Kurnellas, M. et al. Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia. J. Transl. Med. 21, 387 (2023).","journal-title":"J. Transl. Med."},{"key":"77638_CR43","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1212\/01.wnl.0000325058.10218.fc","volume":"71","author":"R Ghidoni","year":"2008","unstructured":"Ghidoni, R., Benussi, L., Glionna, M., Franzoni, M. & Binetti, G. Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology 71, 1235\u20131239 (2008).","journal-title":"Neurology"},{"key":"77638_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11992","volume":"7","author":"AM Nicholson","year":"2016","unstructured":"Nicholson, A. M. et al. Prosaposin is a regulator of progranulin levels and oligomerization. Nat. Commun. 7, 11992 (2016).","journal-title":"Nat. Commun."},{"key":"77638_CR45","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/jnc.14110","volume":"143","author":"X Zhou","year":"2017","unstructured":"Zhou, X., Sullivan, P. M., Sun, L. & Hu, F. The interaction between progranulin and prosaposin is mediated by granulins and the linker region between saposin B and C. J. Neurochem. 143, 236\u2013243 (2017).","journal-title":"J. Neurochem."},{"key":"77638_CR46","unstructured":"Swift, I. Developing Novel Fluid Biomarkers for Progranulin-associated Frontotemporal Dementia (University College London, 2024)."},{"key":"77638_CR47","doi-asserted-by":"crossref","unstructured":"Su\u00e1rez-Calvet, M. et al. CSF progranulin increases in the course of Alzheimer\u2019s disease and is associated with sTREM2, neurodegeneration and cognitive decline. EMBO Mol. Med. 10, e9712 (2018).","DOI":"10.15252\/emmm.201809712"},{"key":"77638_CR48","unstructured":"EurofinsDiscovery. SafetyScreen87 Panel - FR. https:\/\/emea.eurofinsdiscovery.com\/catalog\/safetyscreen87-panel-fr\/P342 Accessed 2026."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77638-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77638-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77638-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:24:25Z","timestamp":1792056265000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77638-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["77638"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-77638-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8405910\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"25 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.K., A.N., and P.L. are named inventors on the following patent applications, assigned to Vesper Bio ApS (certain earlier filings are recorded under the company name Insusense ApS), which claim small-molecule modulators of sortilin and their therapeutic use and which encompass the chemical series to which VES001, the investigational compound evaluated in this study, belongs: WO 2022\/157271, \u201cPyridine derivatives as modulators of sortilin activity\u201d (EP 4281460 A1; US 2024\/0132514 A1); WO 2022\/223805, \u201cModulators of sortilin activity\u201d (EP 4326742 A1; US 2024\/0217922 A1); WO 2022\/238565, \u201cModulators of sortilin activity\u201d (EP 4337674 A2; US 2024\/0294569 A1); WO 2023\/031440, \u201c2-Amino-5,5-dimethylhexanoic acid derivatives as sortilin modulators for use in the treatment of disease of the central nervous system\u201d (EP 4395776 A1; US 2025\/0268854 A1); WO 2023\/161505, \u201cAmino acid based carbamates and\/or ureas for the treatment of sortilin dependent diseases\u201d (EP 4486443 A1; US 2025\/0161321 A1); WO 2024\/047227, \u201cSortilin modulators\u201d (EP 4580750 A1); WO 2024\/089049, \u201cModulators of sortilin activity\u201d (EP 4361165 A1); WO 2024\/184468, \u201cModulators of sortilin activity\u201d (EP 4676917 A1); WO 2024\/184469, \u201cModulators of sortilin activity\u201d (EP 4676914 A1); and WO 2024\/184471, \u201cSortilin modulators\u201d (EP 4676915 A1). These filings claim composition of matter and\/or medical use of the compound class to which VES001 belongs, and M.K., A.N., and P.L. therefore have a financial interest in the successful clinical development and commercialization of VES001, the subject of this manuscript. L.K., I.J.S., S.L.F., D.N., L.F., S.P., G.M.W., A.R., N.S., P.L., O.P., A.N., and M.K. are employees or consultants of Vesper Bio ApS. M.K. and A.N. hold shares and\/or share options in Vesper Bio ApS. A.N. and M.K. are co-founders of Vesper Bio ApS.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"10804"}}